Telomir Pharmaceuticals, Inc., a leader in age-reversal science, has announced significant findings from studies on the copper-binding properties of Telomir-1. These results mark progress in developing Telomir-1 as a treatment for Wilson’s disease and other copper-related disorders. Preclinical in vitro studies conducted by Recipharm and Smart Assays revealed Telomir-1’s strong copper-binding affinity, its selective interaction with copper ions, and its capacity to bind and exchange ions like iron and zinc. These findings position Telomir-1 as a promising candidate for addressing Wilson’s disease, a rare genetic condition caused by mutations in the ATP7B gene that impair copper metabolism, leading to toxic accumulation in the liver and brain. Left untreated, Wilson’s disease can cause severe complications, including liver failure and neurological damage.

Current treatments, such as chelating agents and zinc therapy, have significant limitations, including severe side effects and reduced effectiveness over time, underscoring the urgent need for improved therapies. Telomir-1’s targeted approach to copper regulation offers potential as a safer and more effective alternative. Its development could also qualify for orphan drug designation, expediting regulatory approvals and providing financial incentives.

Building on these results, Telomir is advancing research into various therapeutic areas. Ongoing studies include investigating Telomir-1’s effects on copper regulation for Wilson’s disease, its potential in reversing key metabolic parameters in Type 2 diabetes, and applications in progeria, cancer, Alzheimer’s disease, and metal toxicity. Additionally, Telomir-1’s role in modulating DNA methylation rates is under evaluation for addressing epigenetic changes linked to aging and chronic diseases. The company remains committed to unlocking the drug’s full potential to address root causes of age-related conditions.

Telomir has also shifted its veterinary research strategy. A previous osteoarthritis study was discontinued due to ethical concerns about inducing the condition in animals. The company now plans to collaborate with a veterinary institution to recruit naturally affected elderly dogs and aims to obtain an INAD for pets alongside an IND for human applications.

With plans to optimize manufacturing processes and produce GMP-grade quantities for IND-enabling studies, Telomir targets an IND submission by late 2025 and anticipates first-in-human trials in 2026. The global anti-aging drugs market, valued at $91.05 billion in 2024, is projected to reach $160.24 billion by 2031, driven by advancements in medical research and rising demand for therapies addressing aging-related diseases. Telomir-1 represents a novel approach, aiming to redefine patient care by targeting the root causes of these conditions and enhancing quality of life.